Future studies incorporating breast cancer brain metastasis cohorts with comprehensive follow-up data are warranted to validate the association of DNMT1/RASSF1A expression and methylation status with patient outcomes, thereby strengthening the translational relevance of our findings. This evidence concerns the gene RASSF1 and breast carcinoma.